Gabriele Veroi

Dr. Gabriele Veroi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VVValentina Di Vito
Valentina Di Vito
GVGabriele Veroi
Gabriele Veroi
LRLaura Rizza
Laura Rizza
FRFrancesca Rota Rota
Francesca Rota Rota
ABAndrea Baiocchini
Andrea Baiocchini
RBRoberto Baldelli
Roberto Baldelli
Background: Ovarian neuroendocrine neoplasms (O-NENs) are extremely rare, representing less than 1% of all ovarian neoplasms and under 5% of all neuroendocrine tumors (NETs). They encompass two primary histological subtypes: well-differentiated carcinoids and poorly differentiated neuroendocrine carcinomas, which display distinct biological behaviors and prognoses. The ovary can also be a site of metastasis from extra-ovarian NETs. Owing to their rarity, clinical management lacks standardization, and diagnosis is often incidental following surgery for presumed epithelial ovarian neoplasms. Objectives: This review aims to provide an updated synthesis of current evidence on the epidemiology, pathogenesis, clinical presentation, diagnosis, treatment strategies, and prognosis of O-NENs, highlighting unmet clinical needs. Methods: A literature search was performed on PubMed for the years 2014–2024 using the keywords: “ovarian neuroendocrine tumor”, “ovarian neuroendocrine neoplasm”, “ovarian neuroendocrine carcinoma”, and “ovarian carcinoid”. Only articles published in English were considered. Given the rarity of the disease, in addition to meta-analyses and systematic reviews, relevant case reports and case series were also included to provide a comprehensive clinical picture, yielding 32 eligible articles. Results: Evidence indicates that O-NENs remain understudied, with most data derived from case reports and small series. Clinical presentations vary from asymptomatic masses to hormone-related syndromes, often mimicking other ovarian pathologies. Diagnostic work-up typically follows the same protocol as epithelial ovarian cancer, with the neuroendocrine nature only recognized postoperatively. Treatment strategies are empirical and largely extrapolated from extra-ovarian NETs due to the absence of specific guidelines. Prognosis varies widely depending on histotype, stage, and secretory activity. Conclusions: O-NENs pose significant diagnostic and therapeutic challenges due to their rarity and heterogeneity. Greater clinical awareness, multidisciplinary management, and multicenter research are essential to establish evidence-based protocols and improve patient outcomes.

26 March 2026 in Clinical Oral Investigations
Verified
Journal Article
Closed access
CGCamilla Grenga
Camilla Grenga
Rosanna GuarnieriRosanna Guarnieri
Rosanna Guarnieri
RGRoberto Di Giorgio
Roberto Di Giorgio
GVGabriele Veroi
Gabriele Veroi
GVGabriele Veroi
Gabriele Veroi
EBErsilia Barbato
Ersilia Barbato